BeyondSpring Files 2025 Annual Report on Form 10-K
Rhea-AI Summary
BeyondSpring (NASDAQ:BYSI) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC on March 25, 2026.
The filing includes the company’s audited consolidated financial statements and is available on the SEC website and the company’s investor site. Shareholders may request a free hard copy from Investor Relations.
Positive
- None.
Negative
- None.
News Market Reaction – BYSI
On the day this news was published, BYSI declined 4.17%, reflecting a moderate negative market reaction. Argus tracked a trough of -12.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $71.55M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BYSI is down 1.82% while close peers show mixed moves (e.g., IMMX -2.52%, OSTX +1.41%, ACET +1.34%, ALGS -0.79%, IGMS -2.31%). Momentum scanner only flags ENTX up 3.39%, supporting a stock-specific context.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Conference participation | Positive | +0.7% | IO360 conference presentation spotlighting plinabulin’s mechanism and strategy. |
| Dec 12 | Clinical trial data | Positive | -3.2% | ESMO Asia subset data showing OS benefit in Phase 3 DUBLIN‑3. |
| Dec 11 | Clinical trial data | Positive | +7.9% | Post‑hoc DUBLIN‑3 analyses showing improved survival and fewer brain metastases. |
| Nov 12 | Earnings and update | Neutral | -3.6% | Q3 2025 financials plus pipeline and SEED transaction progress. |
Recent news shows mixed alignment: positive clinical and conference updates sometimes led to gains, while other strong data or financial updates coincided with selloffs.
Over the past months, BeyondSpring reported several key milestones. A Nov 12, 2025 Q3 update detailed NSCLC data and SEED divestiture progress alongside continued operating losses. December 2025 brought multiple Phase 3 DUBLIN‑3 analyses showing survival benefits for plinabulin combinations, with share reactions both positive and negative. In Feb 2026, conference participation on plinabulin had a modestly positive impact. Today’s Form 10‑K filing fits into this cadence of ongoing clinical and financial transparency.
Market Pulse Summary
This announcement simply confirms BeyondSpring’s filing of its Form 10‑K for the year ended December 31, 2025, making audited financial statements and disclosures available through the SEC and company website. Investors can cross‑reference this with recent 8‑K and 13G/A filings to track changes in expenses, cash, and ownership. Key considerations remain the company’s clinical data trajectory, capital position, and any future financing or partnership developments.
Key Terms
form 10-k regulatory
securities and exchange commission regulatory
AI-generated analysis. Not financial advice.
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (“SEC”) on March 25, 2026. The annual report on Form 10-K, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Latest Results” in the Investors section.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 100 Campus Drive, Suite 410, Florham Park, NJ 07932 USA.
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to restoring tumor sensitivity to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet the Company’s expectations regarding the potential safety, the ultimate efficacy or clinical utility of the Company’s product candidates, increased competition in the market, the ability to complete the sale of BeyondSpring’s equity interest in SEED Therapeutics on terms acceptable to BeyondSpring, if at all, the Company’s ability to meet Nasdaq’s continued listing requirements, and other risks described in BeyondSpring’s most recent Form 10-K on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com
FAQ
When did BeyondSpring (BYSI) file its 2025 Form 10-K with the SEC?
Where can investors access BeyondSpring (BYSI) audited consolidated financial statements?
What period does BeyondSpring's (BYSI) 2025 Form 10-K cover?
Does BeyondSpring (BYSI) include audited financial statements in its 2025 Form 10-K?
